Effect of a Monoclonal Antibody to PCSK9 on LDL Cholesterol

Cited by (665)

Items 301–400 of 665

1. Comparative quantitative systems pharmacology modeling of anti-PCSK9 therapeutic modalities in hypercholesterolemia
   Victor V. Sokolov, Gabriel Helmlinger, Catarina A.M. Nilsson, Kirill Zhudenkov, Stanko Skrtic, Bengt Hamrén, Kirill V. Peskov, Eva Hurt‐Camejo, Rasmus Jansson‐Löfmark · 2019 · Journal of Lipid Research
2. Use of imaging and clinical data to screen for cardiovascular disease in asymptomatic diabetics
   Carlos Henrique Reis Esselin Rassi, Timothy W. Churchill, Carlos Augusto Fernandes Tavares, Mateus Guimaraes Fahel, Fabricia P Rassi, Augusto Hiroshi Uchida, BERNARDO LEO WAJCHENBERG, Antônio Carlos Lerário, Edward A Hulten, Khurram Nasir et al. · 2016 · Cardiovascular Diabetology
3. A Review of PCSK9 Inhibitors and their Effects on Cardiovascular Diseases
   Bo Chen, Xin Shi, Yanping Cui, Aiping Hou, Pengjun Zhao · 2019 · Current Topics in Medicinal Chemistry
4. Relationship between alirocumab, PCSK9, and LDL-C levels in four phase 3 ODYSSEY trials using 75 and 150 mg doses
   Jennifer G. Robinson, Michel Farnier, John J.P. Kastelein, Eli M. Roth, Marja‐Riitta Taskinen, Helen Martina Colhoun, Aurélie Brunet, A. Thomas DiCioccio, Guillaume Lecorps, Robert C. Pordy et al. · 2019 · Journal of clinical lipidology
5. Alirocumab: PCSK9 inhibitor for LDL cholesterol reduction
   Tavori, Hagai, Melone, Michelle, Rashid, Shirya · 2014 · Expert Review of Cardiovascular Therapy
6. The next generation of novel low-density lipoprotein cholesterol-lowering agents: Proprotein convertase subtilisin/kexin 9 inhibitors
   Li Shen, Hongchun Peng, Danyan Xu, Shui‐Ping Zhao · 2013 · Pharmacological Research
7. Effect of atorvastatin on testosterone levels
   Muhammad Ismail Shawish, Bahador Bagheri, Vijaya M Musini, Stephen P Adams, James M Wright · 2021 · Cochrane Database of Systematic Reviews
8. Familial Hypercholesterolemia
   Victoria Enchia Bouhairie, Anne Carol Goldberg · 2016 · Endocrinology and Metabolism Clinics of North America
9. Retracted: Advances in the physiological and pathological implications of cholesterol
   Víctor Cortés, Dolores Busso, Pablo Mardones, Alberto Maiz G, Antonio Arteaga, Flavio O. Nervi, Attilio Rigotti · 2013 · Biological reviews/Biological reviews of the Cambridge Philosophical Society · Retracted
10. The discovery of PCSK9 inhibitors: A tale of creativity and multifaceted translational research
    Ahmed Mohamed ElGuindy, Magdi Habib Yacoub · 2013 · Global Cardiology Science and Practice
11. Harnessing publicly available genetic data to prioritize lipid modifying therapeutic targets for prevention of coronary heart disease based on dysglycemic risk
    Vinicius Tragante, Folkert Wouter Asselbergs, Daniel I. Swerdlow, Tom Palmer, Jason H. Moore, Paul I. W. de Bakker, Brendan J. Keating, Michael Vaclav Holmes · 2016 · Human Genetics
12. A Phase I Randomized Study of a Specifically Engineered, pH‐Sensitive PCSK9 Inhibitor RN317 (PF‐05335810) in Hypercholesterolemic Subjects on Statin Therapy
    Matteo G. Levisetti, Tenshang Joh, Hong I. Wan, H Liang, Philippe Forgues, Barry Gumbiner, PD Garzone · 2016 · Clinical and Translational Science
13. The promises of PCSK9 inhibition
    Francine Petrides, Kate Shearston, Mathias Chatelais, Florian Guilbaud, Olivier Meilhac, Gilles C. Lambert · 2013 · Current Opinion in Lipidology
14. Protein convertase subtilisin/kexin type 9 biology in nephrotic syndrome: implications for use as therapy
    Ruxandra Busuioc, Adrian Constantin Covic, Mehmet Kanbay, Maciej Banach, Alexandru Burlacu, Gabriel Mircescu · 2019 · Nephrology Dialysis Transplantation
15. PCSK9 Inhibitors: Focus on Evolocumab and Its Impact on Atherosclerosis Progression
    Maram H. Abduljabbar · 2024 · Pharmaceuticals
16. Safety and efficacy of alirocumab 150 mg every 2 weeks, a fully human proprotein convertase subtilisin/kexin type 9 monoclonal antibody: A Phase II pooled analysis
    Michael J. Koren, Eli M. Roth, James M. McKenney, Daniel A. Gipe, Corinne Hanotin, Anne-Catherine Ferrand, Richard Wu, Robert Dufour · 2015 · Postgraduate Medicine
17. Current Phase II proprotein convertase subtilisin/kexin 9 inhibitor therapies for dyslipidemia
    Paul Lee, Robert Alexander Hegele · 2013 · Expert Opinion on Investigational Drugs
18. Update in Cardiology: Vascular Risk and Cardiac Rehabilitation
    Enrique Galve, Eduardo Alegría, Alberto Cordero, Lorenzo Fácila, Jaime Fernández de Bobadilla, Carla Lluís-Ganella, Pilar Mazón, Carmen de Pablo Zarzosa, José Ramón González‐Juanatey · 2014 · Revista Española de Cardiología (English Edition)
19. CAT‐2003: A novel sterol regulatory element‐binding protein inhibitor that reduces steatohepatitis, plasma lipids, and atherosclerosis in apolipoprotein E*3‐Leiden mice
    Michael Zimmer, Pradeep Bista, Ericka L. Benson, Diana Wing Lee, Feng Liu, Dominic Picarella, Rick B. Vega, Chi B. Vu, Maisy Yeager, Min Ding et al. · 2017 · Hepatology Communications
20. Familial hypercholesterolaemia
    Devaki R. Nair, Mahtab Sharifi, Khalid Al‐Rasadi · 2014 · Current Opinion in Cardiology
21. RNF130 Regulates LDLR Availability and Plasma LDL Cholesterol Levels
    Clifford, Bethan L., Jarrett, Kelsey E., Cheng, Joan, Cheng, Angela, Seldin, Marcus, Morand, Pauline, Lee, Richard, Chen, Mary, Baldan, Angel, de Aguiar Vallim, Thomas Q. et al. · 2023 · Circulation Research
22. The Understanding and Management of Organism Toxicity in Septic Shock
    Kelly R. Genga, Tadanaga Shimada, John H. Boyd, Keith R. Walley, James A. Russell · 2018 · Journal of Innate Immunity
23. Effects of alirocumab on endothelial function and coronary atherosclerosis in myocardial infarction: A PACMAN-AMI randomized clinical trial substudy
    Emrush Rexhaj, Sarah Bär, Rodrigo Soria, Yasushi Ueki, Jonas Dominik Häner, Tatsuhiko Otsuka, Raminta Kavaliauskaite, George C.M. Siontis, Stefan Stortecky, Hiroki Shibutani et al. · 2024 · Atherosclerosis
24. Temas de actualidad en cardiología: riesgo vascular y rehabilitación cardiaca
    Enrique Galve, Almudena Castro, Alberto Cordero, Regina Dalmau, Lorenzo Fácila, Aránzazu García-Romero, Pilar Mazón, Marcelo Sanmartı́n, Angeles Alonso Garcia · 2012 · Revista Española de Cardiología
25. Update on the detection and treatment of atherogenic low-density lipoproteins
    Allan D. Sniderman, Peter O. Kwiterovich · 2013 · Current Opinion in Endocrinology Diabetes and Obesity
26. Alirocumab: A Review in Hypercholesterolemia
    Sarah L. Greig, Emma D. Deeks · 2016 · American Journal of Cardiovascular Drugs
27. A phase 1 study to evaluate the safety and LDL cholesterol–lowering effects of RG7652 , a fully human monoclonal antibody against proprotein convertase subtilisin/kexin type 9
    Amos Baruch, Diana Luca, Robert S. Kahn, Kyra J. Cowan, Maya K. Leabman, Nageshwar R. Budha, Cecilia Chiu, Yan Wu, Daniel Kirchhofer, Andrew S. Peterson et al. · 2017 · Clinical Cardiology
28. PCSK9/LDLR System and Rheumatoid Arthritis-Related Atherosclerosis
    Aikaterini Arida, Aigli‐Ioanna Legaki, Evrydiki Kravvariti, Athanase D. Protogerou, Petros Paul Sfikakis, Antonios Chatzigeorgiou · 2021 · Frontiers in Cardiovascular Medicine
29. Proprotein Convertase Subtilisin/Kexin Type 9: From the Discovery to the Development of New Therapies for Cardiovascular Diseases
    Nicola Ferri · 2012 · Scientifica
30. Clinical efficacy and safety of evolocumab for low-density lipoprotein cholesterol reduction
    Hua Ling, Courtney Henry, Lyon Ra · 2016 · Vascular Health and Risk Management
31. [Retracted] A Systematic Review and Meta‐Analysis of Therapeutic Efficacy and Safety of Alirocumab and Evolocumab on Familial Hypercholesterolemia
    Xiao-Yue Ge, Tiantian Zhu, Hao Zeng, Xin Yu, Juan Li, Shanshan Xie, Jinjin Wan, Huiyao Yang, Keke Huang, Weifang Zhang · 2021 · BioMed Research International · Retracted
32. The role of proprotein convertase subtilisin/kexin 9 (PCSK9) in macrophage activation: a focus on its LDL receptor-independent mechanisms
    Shunsuke Katsuki, Prabhash Kumar Jha, Elena Aïkawa, Masanori Aikawa · 2024 · Frontiers in Cardiovascular Medicine
33. Emerging low-density lipoprotein therapies: Targeting PCSK9 for low-density lipoprotein reduction
    Michael H. Davidson · 2013 · Journal of clinical lipidology
34. PCSK9 inhibition and LDL cholesterol lowering: the biology of an attractive therapeutic target and critical review of the latest clinical trials
    David Rhainds, Benoît J. Arsenault, Jean‐Claude Tardif · 2012 · Clinical Lipidology
35. Anti-PCSK9 antibodies for the treatment of heterozygous familial hypercholesterolemia: patient selection and perspectives
    Alberico Luigi Catapano, Angela Pirillo, Giuseppe Danilo Norata · 2017 · Vascular Health and Risk Management
36. Cell-associated heparin-like molecules modulate the ability of LDL to regulate PCSK9 uptake
    Adri M. Galvan, John S. Chorba · 2018 · Journal of Lipid Research
37. Temas de actualidad en cardiología: riesgo vascular y rehabilitación cardiaca
    Enrique Galve, Eduardo Alegría, Alberto Cordero, Lorenzo Fácila, Jaime Fernández de Bobadilla, Carla Lluís-Ganella, Pilar Mazón, Carmen de Pablo Zarzosa, José Ramón González‐Juanatey · 2014 · Revista Española de Cardiología
38. Acute Intake of Plant Stanol Esters Induces Changes in Lipid and Lipoprotein Metabolism‐Related Gene Expression in the Liver and Intestines of Mice
    Els De Smet, Ronald P. Mensink, Maurice C. J. M. Konings, Gemma Brufau, Albert Kornelis Groen, Rick Havinga, Marleen Schonewille, Anja Kerksiek, Dieter Lütjohann, Jogchum Plat · 2015 · Lipids
39. The effects of single‐ and multiple‐dose administration of bococizumab ( RN 316/ PF ‐04950615), a humanized IgG2Δa monoclonal antibody binding proprotein convertase subtilisin/kexin type 9, in hypercholesterolemic subjects treated with and without atorvastatin: Results from four phase I studies
    Barry Gumbiner, Tenshang Joh, Liang Hong, Hong I. Wan, Matteo G. Levisetti, Alicia M. Vana, David L. Shelton, Philippe Forgues, Stephane Billotte, Jaume Pons et al. · 2017 · Cardiovascular Therapeutics
40. PCSK9 Inhibitors: A New Era in Lipid-Lowering Treatment?
    Miguel Cainzos‐Achirica, Seth Shay Martin, John E. Cornell, Cynthia D. Mulrow, Eliseo Güallar · 2015 · Annals of Internal Medicine
41. Cancer and Cardiovascular Disease: The Conjoined Twins
    Mohammad A. Zmaili, Jafar M. Alzubi, Motasem M. Alkhayyat, Almaza A. Albakri, Feras Alkhalaileh, Joshua Longinow, Rohit Moudgil · 2024 · Cancers
42. A Current Approach to Statin Intolerance
    Rose O. Tompkins, Arthur Z. Schwartzbard, Eugenia Gianos, Edward A A Fisher, HOWARD S. WEINTRAUB · 2014 · Clinical Pharmacology & Therapeutics
43. Efficacy of alirocumab according to background statin type and dose: pooled analysis of 8 ODYSSEY Phase 3 clinical trials
    Alberico Luigi Catapano, L. Veronica Lee, Michael J. Louie, Desmond E. Thompson, Jean Bergeron, Michel Krempf · 2017 · Scientific Reports
44. PCSK9 Inhibitors in Hyperlipidemia: Current Status and Clinical Outlook
    Belinda A. Di Bartolo, Daniel J Scherer, Alex D. H. Brown, Peter James Psaltis, Stephen James Nicholls · 2017 · BioDrugs
45. Effects of 12 weeks of treatment with intravenously administered bococizumab, a humanized monoclonal antibody blocking proprotein convertase subtilisin/kexin type 9, in hypercholesterolemic subjects on high‐dose statin
    Sergio Fazio, David G. C. Robertson, Tenshang Joh, Hong I. Wan, Tom Riel, Philippe Forgues, Charles M. Baum, Pamela D. Garzone, Barry Gumbiner · 2017 · Cardiovascular Therapeutics
46. Indole alkaloid from Nauclea latifolia promotes LDL uptake in HepG2 cells by inhibiting PCSK9
    Mike Okweesi Aggrey, Huihui Li, Wen-Qiong Wang, Yiping Wang, Li‐Jiang Xuan · 2018 · Phytomedicine
47. Interaction between Coffee Drinking and TRIB1 rs17321515 Single Nucleotide Polymorphism on Coronary Heart Disease in a Taiwanese Population
    Yin-Tso Liu, Disline Manli Tantoh, Lee Wang, Oswald Ndi Nfor, Shu‐Yi Hsu, Chien‐Chang Ho, Chia-Chi Lung, Horng‐Rong Chang, Yung‐Po Liaw · 2020 · Nutrients
48. PCSK9 inhibitors
    Bariş Gencer, Gilles C. Lambert, François Mach · 2015 · Swiss Medical Weekly
49. An Update on the Clinical Development of Proprotein Convertase Subtilisin Kexin 9 Inhibitors, Novel Therapeutic Agents for Lowering Low‐Density Lipoprotein Cholesterol
    Hua Ling, Tammy L. Burns, Daniel E. Hilleman · 2013 · Cardiovascular Therapeutics
50. Impact of currently prescribed lipid-lowering drugs on plasma PCSK9 concentration: single or in combination study in rats
    Yan Zhang, Jun Liu, Sha Li, Rui‐Xia Xu, Jing Sun, Jian‐Jun Li · 2014 · Lipids in Health and Disease
51. Development of Antisense Drugs for Dyslipidemia
    Tsuyoshi Yamamoto, Fumito Wada, Mariko Harada‐Shiba · 2016 · Journal of Atherosclerosis and Thrombosis
52. A Quantitative Systems Pharmacology Platform to Investigate the Impact of Alirocumab and Cholesterol-Lowering Therapies on Lipid Profiles and Plaque Characteristics
    Jeffrey E. Ming, Ruth E. Abrams, Derek W. Bartlett, Mengdi Tao, Tu T. Nguyen, Howard K. Surks, Katherine Kudrycki, Ananth Kadambi, Christina M. Friedrich, Nassim Djebli et al. · 2017 · Gene Regulation and Systems Biology
53. Randomised, phase 1, dose-finding study of MEDI4166, a PCSK9 antibody and GLP-1 analogue fusion molecule, in overweight or obese patients with type 2 diabetes mellitus
    Meena Jain, Glenn F. Carlson, W. James Cook, Linda Morrow, Marcella Petrone, Nicholas E. White, Tao Wang, Jacqueline Naylor, Phil Ambery, Charles Lee et al. · 2018 · Diabetologia
54. Genes associated with diabetes: potential for novel therapeutic targets?
    Kazuo Hara, Takashi Kadowaki, Masato Odawara · 2015 · Expert Opinion on Therapeutic Targets
55. PCSK9 monoclonal antibodies: An overview
    Rasha Kaddoura, Bassant Orabi, Amar Mohammad Salam · 2020 · Heart Views
56. PCSK9 Monoclonal Antibodies: New Developments and Their Relevance in a Nucleic Acid–Based Therapy Era
    Ioanna Gouni‐Berthold, Jonas Schwarz, Heiner K. Berthold · 2022 · Current Atherosclerosis Reports
57. Lomitapide: a novel drug for homozygous familial hypercholesterolemia
    Maria D. Panno, Angelo Baldassare Cefalu, Maurizio Rocco Averna · 2014 · Clinical Lipidology
58. Cognition, Statins, and Cholesterol in Elderly Ischemic Stroke Patients: A Neurologist’s Perspective
    Anamaria Jurcău, Aurel Simion · 2021 · Medicina
59. Identifying a novel locus for psoriatic arthritis
    Ashley Budu‐Aggrey, John Bowes, Anne C Barton · 2015 · Rheumatology
60. Dietary high oleic canola oil supplemented with docosahexaenoic acid attenuates plasma proprotein convertase subtilisin kexin type 9 (PCSK9) levels in participants with cardiovascular disease risk: A randomized control trial
    Shuaihua Pu, Celia Rodríguez‐Pérez, Vanu Ramkumar Ramprasath, Antonio Segura‐Carretero, Peter J.H. Jones · 2016 · Vascular Pharmacology
61. Classical monocyte transcriptomes reveal significant anti-inflammatory statin effect in women with chronic HIV
    Erik Ehinger, Yanal Ghosheh, Akula Bala Pramod, Juan Lin, David B. Hanna, Karin Anne Lydia Mueller, Christopher P. Durant, Livia Baas, Qibin Qi, Tao Wang et al. · 2020 · Cardiovascular Research
62. Screening for and Management of Elevated Lp(a)
    Michael B. Boffa, Marlys L. Koschinsky · 2013 · Current Cardiology Reports
63. Relationship of proprotein convertase subtilisin-kexin type 9 levels with resistin in lean and obese subjects
    Arjan J. Kwakernaak, Gilles C. Lambert, Robin P. F. Dullaart · 2012 · Clinical Biochemistry
64. Effect of a Monoclonal Antibody to PCSK9 on LDL Cholesterol
    Evan A. Stein, Scott J. Mellis, George D. Yancopoulos, Neil Stahl, Douglas K. Logan, William Burton Smith, Eleanor A. Lisbon, Maria Gutierrez, Cheryle Webb, Richard Wu et al. · 2012 · Obstetrical & Gynecological Survey
65. Aortic valvular stenosis: Novel therapeutic strategies
    Joanna Natorska, Magdalena Kopytek, Anetta Undas · 2021 · European Journal of Clinical Investigation
66. Guidance on the management of familial hypercholesterolaemia in Hong Kong: an expert panel consensus viewpoint
    Brian Tomlinson, Juliana C.N. Chan, W B Chan, W. Chen, Francis CC Chow, SK Li, Alice P.S. Kong, Ronald C.W., David CW Siu, K. C. B. Tan et al. · 2018 · Hong Kong Medical Journal
67. The Contribution of Low-Frequency and Rare Coding Variation to Susceptibility to Type 2 Diabetes
    Jason A. Flannick · 2019 · Current Diabetes Reports
68. Alternative Treatment Regimens With the PCSK9 Inhibitors Alirocumab and Evolocumab: A Pharmacokinetic and Pharmacodynamic Modeling Approach
    Nina Scherer, Christiane Dings, Michael Böhm, Ulrich Laufs, Thorsten Lehr · 2017 · The Journal of Clinical Pharmacology
69. The APOE ∗ 3-Leiden Heterozygous Glucokinase Knockout Mouse as Novel Translational Disease Model for Type 2 Diabetes, Dyslipidemia, and Diabetic Atherosclerosis
    Marianne G. Pouwer, Suvi E. Heinonen, Margareta Behrendt, Anne‐Christine Andréasson, Arianne van Koppen, Aswin L. Menke, Elsbet Jantine Pieterman, Anita M. van den Hoek, J. Wouter Jukema, Brendan Leighton et al. · 2019 · Journal of Diabetes Research
70. Beyond Statins: Lipid Management to Reduce Cardiovascular Risk
    Robert N. Schuck, Phil Mendys, Ross J. Simpson · 2013 · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy
71. Hipercolesterolemia familiar: artículo de revisión
    Alonso Merchán, Álvaro J. Ruiz, Rafael Campo, Carlos Enrique Prada, Juan Manuel Toro, Róbinson Sánchez, Juan Esteban Gómez‐Mesa, Nicolás I. Jaramillo, Dora Ines Molina, Hernando Vargas‐Uricoechea et al. · 2016 · Revista Colombiana de Cardiología
72. Structural analysis of the LDL receptor-interacting FERM domain in the E3 ubiquitin ligase IDOL reveals an obscured substrate-binding site
    Martinelli, Luca, Adamopoulos, Athanassios, Johansson, Patrik, Wan, Paul T., Gunnarsson, Jenny, Guo, Hongwei, Boyd, Helen, Zelcer, Noam, Sixma, Titia K. · 2020 · Journal of Biological Chemistry
73. A Systematic Approach to Assess the Activity and Classification of PCSK9 Variants
    Kepa B. Uribe, Kévin Chemello, A. Larrea, Asier Benito‐Vicente, Unai Galicia-García, Steeve Bourane, Ali K. Jaafar, Gilles C. Lambert, César Martı́n · 2021 · International Journal of Molecular Sciences
74. Considerations for Use of Pharmacodynamic Biomarkers to Support Biosimilar Development – (I) A Randomized Trial with PCSK9 Inhibitors
    Morasa Sheikhy, Sarah J. Schrieber, Qin Sun, Victoria Gershuny, Murali Krishna Matta, Jane P. F. Bai, Xiulian Du, Giri Vegesna, Aanchal Shah, Kristin Willner Prentice et al. · 2022 · Clinical Pharmacology & Therapeutics
75. Lp-PLA 2 (Lipoprotein-Associated Phospholipase A 2 ) Deficiency Lowers Cholesterol Levels and Protects Against Atherosclerosis in Rabbits
    Jiahuan Chen, Huanyu Zhang, Linquan Li, Xinwei Zhang, Dazhong Zhao, Lingyu Wang, Jiaqi Wang, Ping Chang Yang, Huan Sun, Kun Liu et al. · 2022 · Arteriosclerosis Thrombosis and Vascular Biology
76. Cardiovascular Pharmacogenomics: The Future of Cardiovascular Therapeutics?
    Dan M. Roden · 2012 · Canadian Journal of Cardiology
77. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors, Reality or Dream in Managing Patients with Cardiovascular Disease
    Mohammad Alkhalil · 2018 · Current Drug Metabolism
78. Applications of Functional Genomics for Drug Discovery
    Ami M. Kabadi, Eoin McDonnell, Christopher L. Frank, Lauren Drowley · 2020 · SLAS DISCOVERY
79. Lipid-lowering therapy: Guidelines to precision medicine
    Xin Su, Ye Cheng, Dong Chang · 2020 · Clinica Chimica Acta
80. Cargo Receptor-Mediated ER Export in Lipoprotein Secretion and Lipid Homeostasis
    Xiao Wang, Xiaowei Chen · 2022 · Cold Spring Harbor Perspectives in Biology
81. The Year in Cardiology 2012: focus on cardiovascular disease prevention
    Marietta Charakida, Stefano Masi, John Eric Deanfield · 2013 · European Heart Journal
82. Evolving targets for lipid‐modifying therapy
    Rose Q. Do, Stephen James Nicholls, Gregory G. Schwartz · 2014 · EMBO Molecular Medicine
83. Managing recalcitrant hypercholesterolemia in patients on current best standard of care: efficacy and safety of novel pharmacotherapies
    Amirhossein Sahebkar, Gerald Francis Watts · 2014 · Clinical Lipidology
84. Genetic susceptibility to rheumatoid arthritis and its implications for novel drug discovery
    Annie Yarwood, Stephen Eyre, Jane Worthington · 2016 · Expert Opinion on Drug Discovery
85. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Alirocumab in Healthy Chinese Subjects: A Randomized, Double-Blind, Placebo-Controlled, Ascending Single-Dose Study
    Haiyan Li, Yudong Wei, Zhenhua Yang, Shuang Zhang, Xiuxiu Xu, Mengmeng Shuai, Olivier Vitse, Yiwen Wu, Marie T. Baccara‐Dinet, Yi Zhang et al. · 2020 · American Journal of Cardiovascular Drugs
86. Regression of Atherosclerosis
    Benoît J. Arsenault, Ekaterini A. Kritikou, Jean‐Claude Tardif · 2012 · Current Cardiology Reports
87. Genetics 101 for Cardiologists: Rare Genetic Variants and Monogenic Cardiovascular Disease
    Sali M.K. Farhan, Robert Alexander Hegele · 2012 · Canadian Journal of Cardiology
88. Circulating PCSK9 is a strong determinant of plasma triacylglycerols and total cholesterol in homozygous carriers of apolipoprotein ε2
    Martijn C.G.J. Brouwers, Marleen M. J. van Greevenbroek, Robert J. Konrad, Jason S. Troutt, Nicolaas C. Schaper, Coen D.A. Stehouwer · 2013 · Clinical Science
89. The efficacy of evolocumab in the management of hyperlipidemia: a systematic review
    Lamia AlHajri, Asma AlHadhrami, Shama AlMheiri, Yalwah AlMutawa, Zainab AlHashimi · 2017 · Therapeutic Advances in Cardiovascular Disease
90. Proprotein convertase subtilisin/kexin type 9
    Robert M. Stoekenbroek, John J.P. Kastelein · 2018 · Current Opinion in Cardiology
91. PCSK9—an exciting target for reducing LDL-cholesterol levels
    D. J. Betteridge · 2013 · Nature Reviews Endocrinology
92. Antibodies to PCSK9
    Kara N. Maxwell, Jan L. Breslow · 2012 · Circulation Research
93. Are the PCSK9 inhibitors the panacea of atherosclerosis treatment?
    Evan A. Stein, Traci A. Turner · 2017 · Expert Review of Cardiovascular Therapy
94. Effects of PCSK9 inhibitors on metabolic-associated fatty liver disease: a short review
    Ewelina Jakielska, Paweł Głuszak, Marta Walczak, Wiesław Bryl · 2023 · Gastroenterology Review
95. PCSK9: from molecular biology to clinical applications
    Jonathan Malo, Arun Parajuli, Simon W. Walker · 2019 · Annals of Clinical Biochemistry International Journal of Laboratory Medicine
96. Pharmacodynamic relationship between PCSK9, alirocumab, and LDL-C lowering in the ODYSSEY CHOICE I trial
    Eli M. Roth, John J.P. Kastelein, Christopher Paul Cannon, Michel Farnier, James M. McKenney, Albert Thomas DiCioccio, Aurélie Brunet, Garen Z. Manvelian, William J. Sasiela, Marie T. Baccara‐Dinet et al. · 2020 · Journal of clinical lipidology
97. Is there enough evidence with evolocumab and alirocumab (antibodies to proprotein convertase substilisin-kexin type, PCSK9) on cardiovascular outcomes to use them widely?
    Sheila Anne Doggrell, Kaileen Anne Lynch · 2015 · Expert Opinion on Biological Therapy
98. PCSK9 inhibitors for treating familial hypercholesterolaemia
    Hiroshi Mabuchi, Atsushi Nohara · 2014 · Nature Reviews Endocrinology
99. Circulating proprotein convertase subtilisin-kexin type 9, all-cause mortality, and cardiovascular mortality: The Ludwigshafen Risk and Cardiovascular Health study
    Günther Silbernagel, Hubert Scharnagl, Marcus Edi Kleber, Tatjana Stojaković, Winfried März · 2017 · European Journal of Preventive Cardiology
100. Neuroprotective strategies for acute ischemic stroke: recent progress and future perspectives
     Oh Young Bang · 2017 · Precision and Future Medicine